Breaking: Cellectis (NASDAQ:CLLS) “Outperform” Rating Maintained by Oppenheimer Today; The Target Price Given is $44

June 12, 2018 - By Michael Collier

Cellectis S.A. (NASDAQ:CLLS) Logo

Cellectis (NASDAQ:CLLS) Rating Reaffirmed

They currently have a $44 PT on Cellectis (NASDAQ:CLLS). The target price by Oppenheimer would suggest a potential upside of 43.04 % from the company’s last stock close. This has been revealed in analysts report on 12 June.

Cellectis S.A. (NASDAQ:CLLS) Ratings Coverage

Among 2 analysts covering Cellectis SA (NASDAQ:CLLS), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Cellectis SA had 2 analyst reports since March 14, 2018 according to SRatingsIntel.

The stock increased 1.82% or $0.55 during the last trading session, reaching $30.76. About 112,631 shares traded. Cellectis S.A. (NASDAQ:CLLS) has risen 27.50% since June 13, 2017 and is uptrending. It has outperformed by 14.93% the S&P500.

Analysts await Cellectis S.A. (NASDAQ:CLLS) to report earnings on August, 1. They expect $-0.63 EPS, up 14.86 % or $0.11 from last year’s $-0.74 per share. After $-0.71 actual EPS reported by Cellectis S.A. for the previous quarter, Wall Street now forecasts -11.27 % EPS growth.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company has market cap of $1.29 billion. The firm operates through two divisions, Therapeutics and Plants. It currently has negative earnings. The Company’s lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia and CLL.

More notable recent Cellectis S.A. (NASDAQ:CLLS) news were published by: which released: “Your Daily Pharma Scoop: Cellectis Trial Protocol, Tesaro Takeover Rumor, Kitov Down Before PDUFA” on May 23, 2018, also with their article: “Detailed Research: Economic Perspectives on Galapagos NV, Cellectis SA, MediciNova, Logitech International SA …” published on June 05, 2018, published: “Cellectis SA : Calyxt Announces Successful Closing of $60.9 Million Public Offering” on May 22, 2018. More interesting news about Cellectis S.A. (NASDAQ:CLLS) were released by: and their article: “UPDATE: Cellectis (CLLS) PT Raised to $44 at Oppenheimer” published on June 12, 2018 as well as‘s news article titled: “Cellectis (CLLS) Reports FDA Grants IND Approval for UCART22 in B-ALL” with publication date: June 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: